Fig. 2.
Fig. 2. LMP-1 antisense oligodeoxynucleotide treatment suppresses LMP-1–inducible antiapoptotic genes, Bcl-2 and Mcl-1. Western blot analysis of LMP-1, Bcl-2, and Mcl-1 expression in the EBV-positive lymphoblastoid cell line, X50-7, was performed after exposure to oligodeoxynucleotide (10 μmol/L in the presence of liposomes) for 48 (A) or 72 (B) hours. Lanes 1, untreated control cultured in liposomes; lanes 2, antisense-treated; lanes 3, control oligodeoxynucleotide (SS2)-treated; lane 4, untreated control cultured without liposomes; lane 5, untreated EBV-negative B-cell line, Louckes. Blots were sequentially exposed to anti–LMP-1 antibody, anti–Bcl-2 antibody, and anti–Mcl-1 antibody. Bottom panel shows a representative nonspecific high–molecular-weight band seen on prolonged exposure of the blot using LMP-1 antibody, confirming approximately equivalent amounts of protein loaded per lane.

LMP-1 antisense oligodeoxynucleotide treatment suppresses LMP-1–inducible antiapoptotic genes, Bcl-2 and Mcl-1. Western blot analysis of LMP-1, Bcl-2, and Mcl-1 expression in the EBV-positive lymphoblastoid cell line, X50-7, was performed after exposure to oligodeoxynucleotide (10 μmol/L in the presence of liposomes) for 48 (A) or 72 (B) hours. Lanes 1, untreated control cultured in liposomes; lanes 2, antisense-treated; lanes 3, control oligodeoxynucleotide (SS2)-treated; lane 4, untreated control cultured without liposomes; lane 5, untreated EBV-negative B-cell line, Louckes. Blots were sequentially exposed to anti–LMP-1 antibody, anti–Bcl-2 antibody, and anti–Mcl-1 antibody. Bottom panel shows a representative nonspecific high–molecular-weight band seen on prolonged exposure of the blot using LMP-1 antibody, confirming approximately equivalent amounts of protein loaded per lane.

Close Modal

or Create an Account

Close Modal
Close Modal